Sol-Gel Technologies Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $254.1M
- Price
- $77.73
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.97%
- Volume
- 33.3K
About
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
Quick stats
Shares outstanding3.3M
Computed float853.0K
Float / shares26.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001684693
Websitehttps://www.sol-gel.com
AI Summary
AI-generated1/4
standardneutralearnings
Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Sol-Gel reported Q2 2026 revenue of $0.6 million, down from $17.3 million in the prior year due to the absence of a one-time IP sale, and posted a net loss of $3.7 million or $1.13 per share.
The pivotal Phase 3 trial of SGT-610 for Gorlin syndrome remains on track for top-line results in late November 2026, with management highlighting a lower-than-expected dropout rate of 9%.
The company ended the quarter with $49.3 million in cash and securities, which it expects to fund operations into the first quarter of 2028, while initiating new proof-of-concept studies for HF-BCC and neo-adjuvant BCC surgery.